- Advisers to the U.S Food and Drug Administration on Thursday voted against recommending Spectrum Pharmaceuticals' experimental drug to treat patients with a form of non-small cell lung cancer.
(Reporting by Khushi Mandowara and Mrinalika Roy; Editing by Shailesh Kuber)
Regulated by IMPRESS:
The Independent Monitor
for the Press CIC
IMPRESS, 16-18 New Bridge Street,
London, EC4V 6AG
T: 020 3325 4288
E: complaints@impress.press
W: impress.press